Nuvation Bio (Nuvation Bio) FCF Margin % : 0.00% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Nuvation Bio FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Nuvation Bio's Free Cash Flow for the three months ended in Dec. 2023 was $-15.04 Mil. Nuvation Bio's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Therefore, Nuvation Bio's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

As of today, Nuvation Bio's current FCF Yield % is -8.51%.

The historical rank and industry rank for Nuvation Bio's FCF Margin % or its related term are showing as below:

NUVB.WS's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -149.8
* Ranked among companies with meaningful FCF Margin % only.

Nuvation Bio FCF Margin % Historical Data

The historical data trend for Nuvation Bio's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nuvation Bio FCF Margin % Chart

Nuvation Bio Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Nuvation Bio Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial											-	-	-	-	-

Competitive Comparison of Nuvation Bio's FCF Margin %

For the Biotechnology subindustry, Nuvation Bio's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nuvation Bio's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nuvation Bio's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Nuvation Bio's FCF Margin % falls into.

Nuvation Bio FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Nuvation Bio's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-68.068	/	0
	=	%

Nuvation Bio's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-15.042	/	0
	=	%

Nuvation Bio FCF Margin % Related Terms

Thank you for viewing the detailed overview of Nuvation Bio's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Nuvation Bio (Nuvation Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nuvation Bio Inc (NYSE:NUVB.WS) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

NUVB:USA

Address

1500 Broadway, Suite 1401, New York, NY, USA, 10036

Website

https://www.nuvationbio.com

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company's clinical-stage product candidate is NUV-868, a BD2-selective oral small molecule BET inhibitor. NUV-868 inhibits the protein BRD4, a key member of the BET family that epigenetically regulates a number of important proteins that control tumor growth and differentiation, including oncogenes such as c-myc. Notably, BET proteins have critical biological functions and are found to be altered in many human cancers. It is also developing its proprietary, small molecule Drug-Drug Conjugate (DDC) platform, a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies with parallels to Antibody-Drug Conjugates (ADCs).